Document is current
Any future updates will be listed below
-
Authors
Gaudet, Daniel https://orcid.org/0000-0002-5185-3666
Gonciarz, Malgorzata
Shen, Xi
Leohr, Jennifer K. https://orcid.org/0000-0001-5434-7905
Beyer, Thomas P. https://orcid.org/0000-0001-9153-6879
Day, Jonathan W.
Mullins, Garrett R. https://orcid.org/0009-0000-5320-1023
Zhen, Eugene Y. https://orcid.org/0000-0002-0162-5665
Hartley, Maryalice
Larouche, Miriam
Konrad, Robert J.
Benichou, Olivier
Ruotolo, Giacomo https://orcid.org/0000-0001-5247-5444
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 22 October 2024
Accepted: 9 June 2025
First Online: 10 July 2025
Competing interests
: D.G. reports consulting fees from Amgen, Arrowhead Pharmaceuticals, Chiesi (Amryt), Citeline, CRISPR Therapeutics, Eli Lilly and Company, Flagship Pioneering, Ionis Pharmaceuticals, Medison Pharma, Novo Nordisk, Precision BioSciences, SalioGen Therapeutics, Ultragenyx and Verve Therapeutics; speaking fees from Arrowhead Pharmaceuticals and Ultragenyx; and grants from Alnylam Pharmaceuticals, Applied Therapeutics, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Chiesi (Amryt), Eli Lilly and Company, Esperion Therapeutics, Ionis Pharmaceuticals, Kowa Pharmaceuticals, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Sanofi, The Medicines Company and Ultragenyx. M.G., X.S., J.K.L., T.P.B., J.W.D., G.R.M., E.Y.Z., M.H., R.J.K., O.B. and G.R. are employees and shareholders of Eli Lilly and Company. M.L. declares no competing interests.
